1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On September 21, 2026, abrdn Global Infrastructure Income Fund commenced a rights offering to holders of record on that date, under a dealer manager agreement with UBS Securities LLC. The offer covers up to 10,545,755 new common shares, and the rights expire on October 15, 2026 unless extended, so existing shareholders must decide whether to subscribe before then.
Each common share held at the close of business on September 21, 2026 receives one right; three rights are needed to buy one new common share.
The offer covers up to 10,545,755 common shares of beneficial interest, par value $0.001 per share.
Rights expire at 5:00 p.m. Eastern time on October 15, 2026 unless extended; Equiniti Trust Company, LLC is the subscription agent and EQ Fund Solutions, LLC the information agent.
IB Acquisition Corp. entered into an equity purchase facility of up to $50 million and a securities purchase agreement for senior secured convertible notes, both tied to its pending business combination with GNQ Insilico. The initial PIPE closing of $16,470,588 is set to occur just before the business combination closes, with potential additional closings up to $90 million. The notes carry a 12% interest rate and a 12-month maturity, and their conversion could dilute existing shareholders.
Equity purchase facility allows the company to sell up to $50.0 million of Class A common stock to an institutional investor over up to 36 months.
Initial PIPE closing of $16,470,588 in senior secured convertible notes, with potential additional closings up to $90,000,000.
PIPE notes bear 12% annual interest, rise to an 18% default rate, mature in 12 months and convert at an initial $10.00 per share.
Company issued a $675,000 convertible commitment note to the equity facility investor.
On September 21, 2026, Insulet entered into a Ninth Amendment to its Credit Agreement with Morgan Stanley Senior Funding as administrative agent. The $475 million of existing term loans were replaced with new term loans at a margin 0.25% lower, and revolving commitments rose by $250 million to $750 million, which were undrawn at closing. For shareholders, the filing points to lower borrowing costs and more available credit, though it does not state a dollar effect on earnings.
New term loans of $475 million replaced existing term loans of equal amount, issued at par.
Term SOFR loan margin on new term loans is 1.75%, 0.25% lower than the existing margin, with a 0.00% SOFR floor.
Revolving credit commitments increased by $250 million to $750 million, undrawn at closing; term SOFR margin range cut to 1.25% to 1.75%.
Millrose Properties entered a Commitment and Acceptance on September 21, 2026, adding Flagstar Bank, N.A. as a new lender under its Revolving Credit Facility and increasing the facility's commitments by $50 million to $1.385 billion through the accordion feature. The filing is a financing amendment to an existing credit agreement, and it does not state changes to pricing or other terms.
Revolving Credit Facility commitments increased by $50 million to $1.385 billion
Flagstar Bank, N.A. added as a new lender under the Revolving Credit Facility
Commitment and Acceptance dated September 21, 2026, under Amended and Restated Credit Agreement dated March 25, 2026, as amended August 5, 2026
JPMorgan Chase Bank, N.A. serves as administrative agent
On September 21, 2026, Orion180 Insurance Group Inc. completed its initial public offering of 20,000,000 Class A common shares at $12.00 per share, raising gross proceeds of $240.0 million before underwriting discounts and commissions. The company's amended and restated certificate of formation and bylaws took effect the same day, and five new directors were elected to the board effective September 17, 2026.
Offering: 20,000,000 shares of common stock at $12.00 per share, with gross proceeds of $240.0 million before underwriting discounts and commissions
Charter: authorized capital of 400,000,000 Class A shares, 100,000,000 Class B shares and 50,000,000 undesignated preferred shares, all with $0.001 par value
Board: Kevin Bollinger, Samir Deshpande, Robert V. Deutsch, Lawrence E. McAlee and Kernan "Kip" Oberting elected effective September 17, 2026
Agreements: Registration Rights Agreement and Exchange Agreement with Kenneth Gregg, plus indemnification agreements with directors and executive officers
Calisa Acquisition Corp entered a Prepaid Forward Purchase Agreement on September 15, 2026, with investment funds managed by Harraden Circle Investments, LLC, linked to its pending business combination with Goodvision AI Inc. The Purchaser may buy up to 3,000,000 Ordinary Shares from public holders at no more than the redemption price, which was about $10.31 per share based on trust assets as of August 31, 2026, and the Purchaser will not vote those shares at the shareholder meeting.
Purchaser may buy up to 3,000,000 Ordinary Shares at no more than the redemption price, about $10.31 per share based on trust cash as of August 31, 2026.
Prepayment equal to shares purchased times the redemption price is due from trust funds no later than one business day after the business combination closes.
Unsold forward purchase shares return to the company 12 months after closing; the Seller may terminate earlier by paying the applicable Reset Price.
On September 15, 2026, Alset Inc. bought a convertible promissory note and warrants from DSS, Inc. for $500,000 under a securities purchase agreement. DSS is a related party: Alset holds about a 39.4% equity interest in it, and Chairman and CEO Chan Heng Fai chairs DSS, so the deal is subject to DSS stockholder approval before the note can be converted or the warrants exercised.
Purchase price: $500,000 for a note payable on demand, bearing 3% simple interest per annum
Note convertible into DSS common stock at $0.50 per share; warrants cover 8,000,000 DSS shares at $0.55 per share and expire on their fifth anniversary
Conversion and exercise require DSS stockholder approval
Approved by Alset's Board and Audit Committee; Chan Heng Fai and Chan Tung Moe recused from voting
Brown-Forman completed the sale of $500 million aggregate principal amount of 5.375% notes due October 15, 2031, on September 21, 2026. The company says it may use the proceeds for general corporate purposes, including dividends, stock repurchases, and repaying or repurchasing existing debt such as commercial paper. The filing adds new long-term debt to the company's obligations, with semi-annual interest payments beginning April 15, 2027.
Principal amount: $500 million of 5.375% notes due October 15, 2031
Interest payable semi-annually on April 15 and October 15, beginning April 15, 2027
Offered under a shelf registration on Form S-3 filed March 9, 2026, with U.S. Bank Trust Company as trustee
Underwriters include Barclays Capital, BofA Securities, Citigroup, J.P. Morgan and U.S. Bancorp Investments
Viking Acquisition Corp. II, a special purpose acquisition company, amended and restated its convertible working capital note to its sponsor, raising the principal to $544,080 after a $30,000 advance on September 18, 2026. The note carries no interest, is payable at the earlier of an initial business combination or winding up, and may convert into up to 54,408 private placement-style units at $10.00 each if the sponsor elects.
Principal increased from $514,080 to $544,080 after a $30,000 sponsor advance on September 18, 2026
Note bears no interest and is payable at the earlier of an initial business combination or effective winding up
Sponsor may convert at $10.00 per unit into up to 54,408 New Units, each with one Class A ordinary share and one-third of a warrant exercisable at $11.50
On September 18, 2026, GT Biopharma amended its September 14 securities purchase agreement to add a new purchaser and raise the preferred stock offering to 8,611.111 shares with an aggregate purchase price of $7,750,000. The amendment also gives purchasers rights to buy additional preferred stock for an aggregate purchase price of $31,208,054, and the company increased its designated Series M preferred shares from 41,778 to 43,287, with the shares and warrants sold under Rule 506(b) and a resale registration statement to be filed.
Preferred stock offering increased to 8,611.111 shares of Series M 10% Convertible Preferred Stock, with an aggregate stated value of $8,611,111.11 and an aggregate purchase price of $7,750,000.
Purchasers may elect additional preferred stock purchases (Greenshoe Rights) with an aggregate stated value of up to $34,675,615 for an aggregate purchase price of $31,208,054.
Certificate of Increase filed September 18, 2026 raises designated Series M preferred shares from 41,778 to 43,287.
Company agreed to file a resale registration statement within 30 days after the initial closing and after each Greenshoe closing.
OppFi Inc. disclosed that a subsidiary borrowed $75.0 million under a senior secured multi-draw term loan dated August 10, 2026, with a fixed rate of 12.50% per annum before its pending BNCCORP acquisition closes. The company said the proceeds will support growth in finance receivables and for working capital and general corporate purposes. Shareholders should note the loan carries a 1.25% original issue discount, semi-annual amortization and covenants, and that a further $25.0 million remains available through February 10, 2027.
Initial borrowing of $75.0 million on September 15, 2026; maximum commitment $100.0 million
Fixed rate of 12.50% per annum before the BNCCORP acquisition closes, rising to 13.50% after
Maturity is four years from September 15, 2026; loans require semi-annual amortization of 10% of principal
BNCCORP stockholders adopted the merger agreement at a special meeting on September 17, 2026; regulatory approvals remain pending
On September 15, 2026, DSS entered into a securities purchase agreement with Alset Inc., a related party under common control of the Chairman, under which Alset lent DSS $500,000 in exchange for a convertible demand note and warrants. The note and warrants could add up to 8,000,000 shares of common stock, and their conversion or exercise requires stockholder approval, so the deal may dilute existing shareholders if approved.
Alset lent DSS $500,000, payable on demand, with simple interest at 3% per year.
The note converts at $0.50 per share, and warrants for up to 8,000,000 shares carry an exercise price of $0.55 per share.
Both the note and warrants have five-year terms, and stockholder approval is required before conversion or exercise.
The Board and Audit Committee approved the transaction; several directors also serve at Alset.
CDW LLC and CDW Finance Corporation completed the sale of $1.5 billion in senior notes in three tranches, guaranteed by parent CDW Corporation. The notes carry fixed coupons from 5.700% to 6.350% and mature between 2029 and 2033, so the company takes on new debt that must be repaid with interest.
2029 Notes: $600 million at 5.700%, maturing September 21, 2029
2032 Notes: $500 million at 6.100%, maturing January 15, 2032
2033 Notes: $400 million at 6.350%, maturing September 21, 2033
TechPrecision's subsidiary Ranor and other borrowers signed a fifteenth amendment to their loan agreement with Beacon Bank & Trust on September 15, 2026. The amendment extends the maturity of the $4.5 million revolving line of credit from September 15, 2026 to October 16, 2026, a short extension of the existing facility.
Revolving line of credit maximum principal amount: $4,500,000
Maturity extended from September 15, 2026 to October 16, 2026
Amendment executed September 15, 2026 with Beacon Bank & Trust, successor by merger to Berkshire Bank
Credit Acceptance extended its $500.0 million Term ABS 2019-2 financing and its warehouse facility, both now running to September 15, 2028. The Term ABS rate rose from 5.43% to 5.83%, while the warehouse facility rate fell from SOFR plus 185 basis points to SOFR plus 175 basis points. The filing describes these as routine financing amendments with no other material changes, and it does not address earnings or guidance.
Term ABS 2019-2 ($500.0 million) revolving period extended from September 15, 2026 to September 15, 2028; interest rate increased from 5.43% to 5.83%
Warehouse Facility II amortization date extended from September 20, 2027 to September 15, 2028; rate cut from SOFR plus 185 to SOFR plus 175 basis points
$180.0 million outstanding under Warehouse Facility II as of September 15, 2026
Electra Therapeutics, Inc. closed its initial public offering on September 21, 2026, selling 23,333,334 shares of common stock at $15.00 per share, for approximately $350.0 million in gross proceeds before underwriting discounts and offering expenses. The company also filed an amended and restated certificate of incorporation and adopted amended and restated bylaws effective on the closing date.
IPO: 23,333,334 shares of common stock sold at $15.00 per share
Gross proceeds of approximately $350.0 million before underwriting discounts and estimated offering expenses
Restated certificate of incorporation filed with Delaware and restated bylaws adopted, both effective September 21, 2026
Full terms are described in the final prospectus filed September 18, 2026 under Rule 424(b)
InspireMD amended some of its outstanding Series J and Series K warrants with certain holders, lowering the exercise price on the affected shares to $0.7674 and tying their expiration to the anticipated FDA approval of CGuard Prime 80 cm. The company says that if the warrants are exercised in full, they could bring in up to $11 million in gross proceeds, which it expects to help fund the product launch, while existing shareholders face the potential dilution that would follow.
Amendments cover 50% of the Series J warrant shares and all Series K warrant shares held by participating holders, with the rest of the Series J shares unchanged at $1.3827.
New termination date is 5:00 p.m. Eastern on the earlier of May 15, 2028 or 20 trading days after the company announces FDA approval of CGuard Prime 80 cm, which it expects in Q4 2026.
The press release says up to $11 million in gross proceeds if the warrants are exercised in full; no new warrants were issued.
Some participating warrant holders are members of the company's board of directors.
Magnachip Semiconductor agreed on September 18, 2026, to issue 1,461,988 common shares to Navitas Semiconductor for $5 million in a private placement. The company says the investment builds on the strategic partnership with Navitas, under which Magnachip licenses Navitas' GeneSiC silicon carbide technology, and the closing is expected on or about September 24, 2026. Shareholders will see new shares issued, and Magnachip must file a resale registration statement on Form S-3 within 30 days after closing.
Stock purchase agreement dated September 18, 2026, with Navitas for 1,461,988 shares at $3.42 per share
Aggregate proceeds of $5 million; closing expected on or about September 24, 2026, subject to customary conditions
Shares were not registered under the Securities Act and were issued under Section 4(a)(2) or Rule 506 of Regulation D
Magnachip must file a Form S-3 resale registration within 30 days after closing
On September 18, 2026, Clearwater Paper entered a $200 million revolving credit facility and a $275 million term loan with AgWest Farm Credit, PCA as agent, replacing its existing term revolver and ABL credit facilities. Proceeds were used to pay off the ABL facility and to redeem in full the $275 million 4.750% Senior Notes due 2028 on October 3, 2026, and the new credit agreement matures on September 18, 2031, extending the company's debt maturities.
The $200 million revolving facility had about $15 million drawn at closing, and the $275 million term loan was fully funded.
The company will redeem its $275 million 4.750% Senior Notes due 2028 on October 3, 2026 and paid $1.7 million of accrued interest through the redemption date.
Initial interest rate on the term loan and Refinancing Date revolver borrowings is 8.25% per annum; the term loan amortizes $5.5 million annually from December 1, 2027, and the facility matures September 18, 2031.
Kosmos Energy issued a notice of partial redemption on September 18, 2026, for $25 million of its 7.750% senior notes due 2027. Redemption is expected to occur on September 30, 2026, and the company may pursue additional optional redemptions before the notes' final maturity.
Partial redemption of $25,000,000 aggregate principal amount of 7.750% senior notes due 2027
Notice issued September 18, 2026; redemption expected September 30, 2026
Company may elect additional optional redemptions before final maturity
Knightscope filed a prospectus supplement on September 21, 2026 to increase the maximum number of Class A common shares it can issue under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC. The filing does not state the new share cap or any sales made, so the size of the potential dilution to shareholders cannot be determined from this document.
Prospectus supplement filed September 21, 2026 under Form S-3 (File No. 333-286404), declared effective April 11, 2025
Increases the maximum number of Class A common shares issuable under the At The Market Offering Agreement dated February 1, 2023
Legal opinion from Haynes and Boone, LLP filed as Exhibit 5.1
WESCO's subsidiary Wesco Distribution amended its ABL revolving credit facility and its receivables securitization facility on September 17, 2026. The amendments extend both facilities, raise the commitments and purchase limits, and lower interest and drawn spreads, giving the company more borrowing capacity on longer terms.
ABL Facility commitments rise from $1,725 million to $1,850 million, with maturity extended to September 17, 2031.
Receivables Facility purchase limit rises from $1,550 million to $1,750 million, with termination date extended to September 17, 2029.
Interest rate spreads on the ABL Facility and drawn spreads on the Receivables Facility decrease under the amendments.
Barclays Bank PLC is administrative agent for the ABL Facility; PNC Bank, National Association is administrator for the Receivables Facility.
Axon issued and sold $1,150.0 million of 0% convertible senior notes due September 15, 2031, on September 18, 2026, including $150.0 million from the full exercise of the underwriters' over-allotment option. The initial conversion price is about $652.06 per share, compared with a last reported sale price of $442.08 on September 15, 2026, so conversion could dilute existing shareholders. The company said capped call transactions are expected to reduce that potential dilution, subject to a cap price of $1,049.94.
Principal of $1,150.0 million issued September 18, 2026, including $150.0 million from full exercise of the over-allotment option
Notes bear no regular interest and mature September 15, 2031; initial conversion rate of 1.5336 shares per $1,000 principal
Expected net proceeds of about $1,134.3 million if the over-allotment option is exercised in full, with about $114.9 million used for capped call transactions
Holders may require repurchase at par on or around March 20, 2031, and the company may redeem for cash on or after September 20, 2029, under specified conditions
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.